BIIB Biogen Inc. Stock Quote

BIIB [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	21.42	EPS (ttm)	10.22	Insider Own	0.66%	Shs Outstand	148.00M	Perf Week	-3.09%
Market Cap	32.95B	Forward P/E	11.64	EPS next Y	18.80	Insider Trans	0.00%	Shs Float	145.87M	Perf Month	-7.22%
Income	1.55B	PEG	-	EPS next Q	3.34	Inst Own	86.60%	Short Float	1.69%	Perf Quarter	-15.78%
Sales	11.10B	P/S	2.97	EPS this Y	-21.10%	Inst Trans	0.02%	Short Ratio	1.54	Perf Half Y	-33.49%
Book/sh	70.47	P/B	3.11	EPS next Y	-1.78%	ROA	6.40%	Target Price	282.23	Perf Year	-18.27%
Cash/sh	19.64	P/C	11.15	EPS next 5Y	-15.00%	ROE	14.50%	52W Range	214.88 - 468.55	Perf YTD	-8.74%
Dividend	-	P/FCF	13.63	EPS past 5Y	10.10%	ROI	19.60%	52W High	-53.27%	Beta	0.46
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	4.50%	Gross Margin	82.50%	52W Low	1.89%	ATR	8.55
Employees	9100	Current Ratio	1.70	Sales Q/Q	-17.70%	Oper. Margin	17.30%	RSI (14)	38.42	Volatility	3.38% 3.80%
Optionable	Yes	Debt/Eq	0.70	EPS Q/Q	-50.40%	Profit Margin	13.90%	Rel Volume	0.66	Prev Close	219.60
Shortable	Yes	LT Debt/Eq	0.60	Earnings	Oct 20 BMO	Payout	0.00%	Avg Volume	1.60M	Price	218.94
Recom	2.30	SMA20	-6.62%	SMA50	-7.89%	SMA200	-24.90%	Volume	1,102,108	Change	-0.30%

Jan-13-22

Downgrade

Guggenheim

Buy → Neutral

$290 → $202

Jan-12-22

Downgrade

Piper Sandler

Overweight → Neutral

$362 → $216

Dec-10-21

Resumed

Raymond James

Mkt Perform

Dec-09-21

Resumed

Wells Fargo

Equal Weight

$250

Dec-06-21

Initiated

Goldman

Neutral

$271

Nov-19-21

Initiated

BMO Capital Markets

Outperform

$315

Sep-23-21

Initiated

Needham

Buy

$400

Jun-18-21

Upgrade

Piper Sandler

Neutral → Overweight

$384 → $450

Jun-14-21

Reiterated

Truist

Buy

$458 → $647

Jun-11-21

Upgrade

Bernstein

Mkt Perform → Outperform

$500

Jun-10-21

Upgrade

UBS

Neutral → Buy

Jun-08-21

Upgrade

William Blair

Mkt Perform → Outperform

Jun-08-21

Upgrade

Robert W. Baird

Underperform → Neutral

$216 → $382

Jun-08-21

Upgrade

Citigroup

Sell → Neutral

$200 → $440

Jun-08-21

Upgrade

Atlantic Equities

Underweight → Neutral

$415

Jun-08-21

Reiterated

Stifel

Buy

$346 → $446

Jun-08-21

Reiterated

RBC Capital Mkts

Sector Perform

$259 → $400

Jun-08-21

Reiterated

Morgan Stanley

Overweight

$343 → $455

Jun-08-21

Reiterated

Jefferies

Buy

$450 → $500

Jun-08-21

Reiterated

H.C. Wainwright

Buy

$305 → $452

Jan-27-22 08:27PM	Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics The Wall Street Journal
07:15PM	Biogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologics Bloomberg
07:10PM	Biogen stock pops after agreement to sell Samsung part of joint venture MarketWatch
06:50PM	Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion GlobeNewswire
05:38PM	Cambiar Investors Llc Buys iShares MSCI EAFE ETF, Barclays PLC, Constellation Brands Inc, Sells ... GuruFocus.com
05:38PM	Nbt Bank N A Buys Vanguard High Dividend Yield Indx ETF, Dow Inc, Global X U.S. ... GuruFocus.com
03:25PM	Biogen lays out plans for confirmatory study of Alzheimer's drug American City Business Journals
03:01PM	Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline Zacks
01:38PM	Oxler Private Wealth LLC Buys Ford Motor Co, Verizon Communications Inc, Zoom Video ... GuruFocus.com
09:43AM	Biogen Will Recruit Minority Participants for New Aduhelm Trial Barrons.com
07:30AM	Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM® GlobeNewswire
Jan-26-22 05:38PM	Resonant Capital Advisors, LLC Buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National ... GuruFocus.com
01:38PM	Eastern Bank Buys Eastman Chemical Co, Vanguard S&P 500 ETF, Honeywell International Inc, ... GuruFocus.com
09:38AM	Optas, LLC Buys Vanguard Small Cap ETF, Vanguard ESG U.S. ... GuruFocus.com
09:38AM	Covenant Asset Management, LLC Buys Marvell Technology Inc, Zebra Technologies Corp, Staar ... GuruFocus.com
Jan-25-22 05:50PM	Biogen Inc. (BIIB) Stock Moves -1.06%: What You Should Know Zacks
12:33PM	Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA Zacks
09:38AM	Private Ocean, LLC Buys Regal Rexnord Corp, T-Mobile US Inc, Vanguard Total Bond Market ETF, ... GuruFocus.com
Jan-24-22 06:00PM	Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
05:38PM	LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ... GuruFocus.com
09:38AM	Wedge Capital Management L L P Buys Fidelity National Financial Inc, Arista Networks Inc, ... GuruFocus.com
Jan-23-22 11:05AM	Is It Time to Sell Biogens Parts After the Alzheimers Drug Debacle? Barrons.com
Jan-22-22 10:00AM	Is Biogen a Buy? Motley Fool
Jan-21-22 07:00PM	Biogen After the Alzheimers Drug Debacle: Time to Sell the Parts? Barrons.com
05:38PM	Alhambra Investment Partners LLC Buys VanEck Short Muni ETF, Vanguard Short-Term Bond ETF, ... GuruFocus.com
01:38PM	Darwin Advisors, LLC Buys iShares U.S. Technology ETF, First Trust Exchange-Traded Fund VIII ... GuruFocus.com
07:00AM	CORRECTED-Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new drugs Reuters
Jan-18-22 01:38PM	Absher Wealth Management, Llc Buys Amgen Inc, Visa Inc, Lockheed Martin Corp, Sells General ... GuruFocus.com
09:41AM	Why Biogen Could Need to Sell for Parts Barrons.com
09:38AM	Abacus Planning Group, Inc. Buys Distillate U.S. ... GuruFocus.com
09:07AM	Ionis' (IONS) Partner to Begin New Huntington's Disease Study Zacks
Jan-17-22 06:40AM	Is Biogen a Buy After the Latest Aduhelm Disaster? Motley Fool
Jan-15-22 06:36AM	Where Will Biogen Be in 5 Years? Motley Fool
Jan-14-22 06:00PM	Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
05:38PM	Culbertson A N & Co Inc Buys The Travelers Inc, WisdomTree U.S. ... GuruFocus.com
10:11AM	Biogen Inc. -- Moody's reviews Biogen's Baa1 ratings for downgrade Moody's
06:10AM	4 Biotech Acquisitions We'd Like to See in 2022 Motley Fool
Jan-13-22 09:38PM	Richard P Slaughter Associates Inc Buys JPMorgan Equity Premium Income ETF, Vanguard FTSE ... GuruFocus.com +5.03%
04:08PM	Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure Investor's Business Daily
03:34PM	Biogen eyes potential acquisitions - Stat News Reuters
03:32PM	Biogen eyes potential acquisitions - Stat News Reuters
01:10PM	Biogen Recognized as One of America's Most JUST Companies News Direct
11:27AM	3 Biotech Stocks to Buy That Are Under Severe Pressure InvestorPlace
09:03AM	UPDATE 2-Biogen seeks dialogue with U.S. CMS about Alzheimer's drug coverage decision Reuters
08:33AM	Biogen says yet to speak with CMS about coverage of Alzheimer's drug Reuters
08:20AM	These S&P 500 stocks have cratered, but analysts think 12 can turn it around with rebounds of up to 70% MarketWatch
08:01AM	Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug MarketWatch
Jan-12-22 05:38PM	First Hawaiian Bank Buys iShares Core S&P 500 ETF, Vanguard Russell 1000 Growth Index Fund, ... GuruFocus.com -6.70%
04:06PM	Biogen Stock Tumbles As Medicare Delivers Another Obstacle To Its Alzheimer's Drug Investor's Business Daily
01:15PM	Biogen features on 'Shkreli Awards' American City Business Journals
01:12PM	Nasdaq 100 extends gains, Chinese ADRs rise, meme stocks mixed, Biogen stock plunges Yahoo Finance Video
11:32AM	Why Biogen Stock Is Sinking Today Motley Fool
11:30AM	Medicare to Consider Lowering Part B Premiums Kiplinger
11:10AM	BioMarin CEO: There are biotech companies 'that probably should not be on the market today Yahoo Finance Video
11:05AM	S&P 500 Takes Red-Hot Inflation in Stride as Materials, Tech Shine Investing.com
11:01AM	Centene vice chairman talks CMS changes, the Alzheimers drug, and COVID-19 hospitalizations Yahoo Finance Video
10:34AM	Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs Zacks
10:14AM	S&P 500 Inches Higher Following Hottest Inflation Report in Decades Investing.com
10:13AM	Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates Zacks
10:13AM	Medicare pulls back on coverage of an Alzheimers drug MarketWatch
10:02AM	Biogen Stock Chart Says: Dip Gives the Bulls an Unusual Opportunity TheStreet.com
09:44AM	Biogens stock tumbles after the U.S. proposes restricting access to its Alzheimers disease drug MarketWatch
09:33AM	Biogen Got Bad News on Its Alzheimers Drug. Why It Hurt Eli Lilly, Too. Barrons.com
09:08AM	Will This Stock's Pain Be Medicare's Gain? Motley Fool
08:11AM	Biogen Stock Is Tumbling Because Its Alzheimers Drug Just Got Some Really Bad News Barrons.com
07:21AM	Biogen shares slide as Medicare restricts cover of Alzheimer's treatments Reuters
06:53AM	CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply Benzinga
06:50AM	Biogen Stock Is Tumbling Because Its Alzheimers Drug Just Got Some Really Bad News Barrons.com
06:49AM	Powell Said All the Right Things. But Inflation Has a Mind of Its Own. Barrons.com
05:14AM	Biogen Stock Slumps To 2-Year Low As Medicare Limits Alzheimer's Drug Coverage TheStreet.com
03:04AM	Biogen, Philips, Lucid Fall Premarket; Ocugen, Didi Global Rise Investing.com
01:43AM	U.S. CPI, Chinese Easing Hopes, Record Hospitalizations - What's Moving Markets Investing.com
12:52AM	Stocks Higher, Inflation In Focus, Oil, Biogen and Amazon - Five Things You Must Know TheStreet.com
12:48AM	Biogen Plunges as Medicare Cover of Alzheimers Therapy is Restricted Investing.com
Jan-11-22 07:04PM	Medicare to Pay for Biogens New Alzheimers Drug in Clinical-Trial Patients The Wall Street Journal
06:55PM	Biogen Stock Is Tumbling Because Its Alzheimers Drug Has Hit Another Snag Barrons.com
05:01PM	UPDATE 2-U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients Reuters
04:58PM	Medicare plans to cover Biogen drug only for patients in clinical trials American City Business Journals
04:49PM	Biogen stock falls more than 6% after Medicare plans coverage limits for pricy Alzheimer's drug MarketWatch
02:05PM	Medicare Will Only Cover Pricey New Alzheimer's Drug For Trial Patients TheStreet.com
07:00AM	Future of Biogen's Aduhelm hinges on U.S. Medicare Alzheimer's coverage Reuters
Jan-10-22 12:10PM	Biogen defends Alzheimer's drug, highlights pipeline at J.P. Morgan conference American City Business Journals
12:00PM	Medicare asked to reassess 2022 premium hikes after Aduhelm price cut Reuters
07:00AM	Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis GlobeNewswire
04:15AM	Biogens Alzheimers Drug Has a Shot at Redemption This Week. Will It Be Enough? Barrons.com
Jan-07-22 05:38PM	McAdam, LLC Buys BTC iShares Core MSCI EAFE ETF, Vanguard Mid-Cap Value ETF, VANGUARD INDEX ... GuruFocus.com
03:46PM	Biogens Alzheimers Drug Has Another Shot at Success Barrons.com
06:37AM	Better Buy: Vertex Pharmaceuticals vs. Biogen Motley Fool
05:10AM	One Biogen Inc. (NASDAQ:BIIB) insider upped their stake by 44% in the previous year Simply Wall St.
Jan-06-22 05:36AM	The Petri Dish: Janssen inks two local deals, Biogen licenses new drug American City Business Journals
05:30AM	Stakes are high as Biogen faces investors next week at JP Morgan conference American City Business Journals
Jan-05-22 05:50PM	Biogen Inc. (BIIB) Stock Moves -1.02%: What You Should Know Zacks
12:10PM	Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again Zacks
11:20AM	Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis Zacks
Jan-04-22 03:30PM	How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimers Drug The Wall Street Journal
08:50AM	Biogen is Tradable After Long Slide: Guilfoyle TheStreet.com
07:34AM	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA GlobeNewswire
07:30AM	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA PR Newswire
Jan-03-22 06:00PM	Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
06:19AM	Medicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT Benzinga

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kramer Robin	Chief Accounting Officer	Dec 03	Option Exercise	223.92	339	75,909	1,210	Dec 07 04:09 PM
Izzar Rachid	Head of Alzheimer's Disease	Dec 02	Option Exercise	228.52	372	85,009	1,271	Dec 06 04:14 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01	Option Exercise	338.24	6,005	2,031,131	4,864	Sep 03 04:08 PM
Sandrock Alfred	Head of Research & Development	Jun 07	Sale	440.00	7,672	3,375,680	10,169	Jun 09 07:05 PM
Guindo Chirfi	Head of Glob Prod Strat & Com	Jun 07	Sale	440.00	3,087	1,358,280	2,919	Jun 09 07:04 PM
Posner Brian S	Director	Jun 04	Sale	274.17	360	98,701	7,400	Jun 07 07:02 PM
Sandrock Alfred	EVP, Research & Development	Feb 12	Option Exercise	0.00	4,454	0	19,715	Feb 17 05:01 PM
Vounatsos Michel	Chief Executive Officer	Feb 12	Option Exercise	0.00	16,289	0	60,194	Feb 17 05:03 PM
Kramer Robin	SVP, Chief Accounting Officer	Feb 12	Option Exercise	0.00	333	0	706	Feb 17 04:59 PM
Guindo Chirfi	EVP Glob. Prod Strat and Comm	Feb 12	Option Exercise	0.00	3,156	0	6,946	Feb 17 04:58 PM
Gregory Ginger	EVP, Human Resources	Feb 12	Option Exercise	0.00	2,923	0	9,288	Feb 17 04:56 PM
Galdes Alphonse	EVP Pharmaceutical Oper & Tech	Feb 12	Option Exercise	0.00	1,573	0	4,765	Feb 17 04:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 12	Option Exercise	0.00	4,355	0	43,509	Feb 17 04:52 PM
Mantas Jesus B	Director	Feb 09	Buy	267.00	898	239,766	2,943	Feb 10 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience